Headache

>

Latest News

FDA accepts sBLA to expand fremanezumab-vfrm indication | Image Credit: © Araki Illustrations - © Araki Illustrations  - stock.adobe.com.
FDA accepts sBLA to expand fremanezumab-vfrm indication for episodic migraines in children

April 7th 2025

If approved, the expanded indication would include children and adolescents aged 6 to 17 years who weigh 99 lbs (45 kg) or more.

Fremanezumab for episodic migraine prevention demonstrates positive phase 3 dataLatest revision | Image Credit: © Jan H. Andersen - © Jan H. Andersen - stock.adobe.com.
Fremanezumab for episodic migraine prevention demonstrates positive phase 3 data

December 4th 2024

Nerivio REN wearable now FDA-cleared to treat migraines in children 8 years and up | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.
Nerivio REN wearable now FDA-cleared to treat migraines in children 8 years and up

November 15th 2024

Image Credit: Contemporary Pediatrics
OnabotulinumtoxinA shows promise for treating chronic migraine

June 17th 2024

Posttraumatic headache phenotype associated with symptom burden, quality of life after concussion | Image Credit: © Satjawat - © Satjawat - stock.adobe.com.
Posttraumatic headache phenotype associated with symptom burden, quality of life after concussion

July 7th 2023

More News

© 2025 MJH Life Sciences

All rights reserved.